Year: 2024

NEW YORK and LEAMINGTON, Ontario, Dec. 19, 2024 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global lifestyle and consumer packaged goods company, today announced that the Company will release its financial results for the second quarter ended November 30, 2024 before the financial market opens on January 9, 2025. Live Conference Call and Audio Webcast Tilray will host a live conference call, which will be webcast, to discuss these results at 8:30 a.m. Eastern Time. The webcast can be accessed on the Investors section of Tilray’s website at www.Tilray.com. About Tilray Brands Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and...

IRVINE, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global leader in IoT compute and connectivity IoT solutions, today announced that Saleel Awsare, CEO and Brent Stringham, Interim CFO, will deliver in-person presentations on Tuesday, Jan. 14, and Wednesday, Jan. 15, 2025, at the 27th Annual Needham Growth Conference at the Lotte New York Palace Hotel in New York City. The live audio webcast and replay of the presentations will be available approximately two hours following the live event and will be accessible for 90 days in the investor relations section of the Lantronix website. Interested investors should contact Lantronix at investors@lantronix.com for availability for a one-on-one meeting. For more information on the conference, visit the Needham Growth Conference website here. About Lantronix    Lantronix...

Investigational REGN7508 (catalytic domain) and REGN9933 (A2 domain) are being evaluated for their potential to control thrombosis while minimizing bleeding risk in a variety of patient populations and clinical settings Evaluated against current standards of care, single doses of REGN7508 and REGN9933 administered 12 to 24 hours after total knee replacement demonstrated robust antithrombotic effects Phase 3 program to be initiated in 2025 TARRYTOWN, N.Y., Dec. 19, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive Phase 2 results for two novel monoclonal antibodies targeting distinct domains of Factor XI. REGN7508 (catalytic domain) is designed to maximize anticoagulant activity while minimizing bleeding risk, and REGN9933 (A2 domain) is designed to provide an additional option for...

AleAnna Secures A Contract To Sell Its Gas To Shell Energy Europe Ltd, A Leading Natural Gas, Power And Environmental Trading Company Across European MarketsAleAnna has signed a multi-year gas sales agreement with Shell Energy Europe Ltd for its share of the Longanesi production to ensure secure natural gas Longanesi production is expected to commence in Q1 2025DALLAS and ROME, Dec. 19, 2024 (GLOBE NEWSWIRE) — AleAnna (Nasdaq: ANNA), a leading energy company in Italy, has signed an exclusive gas supply agreement with Shell Energy Europe Ltd. This significant contract reinforces AleAnna’s long-term commitment to Italy and its flagship Longanesi project. The gas will be supplied from the Longanesi Field, located in the Emilia-Romagna region of Italy, with production scheduled to commence in the first quarter of 2025. This agreement...

PyroGenesis to receive 17,968,873 units comprised of one common share plus one common share purchase warrant from HPQ Silicon Inc. MONTREAL, Dec. 19, 2024 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis”) (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY), a high-tech company that designs, develops, manufactures and commercializes advanced plasma processes and sustainable solutions, which are geared to reduce greenhouse gases (GHG) and address environmental pollutants, announced today an agreement with HPQ Silicon Inc. (“HPQ”) to resolve an outstanding liability of $4,941,440 owed to PyroGenesis, using a debt-to-equity conversion. Under the agreement, the outstanding liability will be converted into 17,968,873 units at a price of $0.275 per unit. Each unit will be comprised of one common share of HPQ and one common...

Dr. Michael Bumby joins XORTX as Chief Financial Officer CALGARY, Alberta, Dec. 19, 2024 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Dr. Michael Bumby, a biotech/pharma industry veteran, as its Chief Financial Officer replacing James Fairbairn, the Company’s current Chief Financial Officer. Dr. Bumby, DVM, MBA, is currently a director and audit committee chair of MediPharm Labs following their successful acquisition of VIVO Cannabis Inc. where Dr. Bumby was CFO for six years. Dr. Bumby brings over 20 years of finance and leadership experience in the biotech/pharma industry. He had a 14-year career at Eli Lilly, including...

MELBOURNE, Australia, Dec. 19, 2024 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has completed the installation of two new cyclotrons at Telix Manufacturing Solutions (TMS) in Brussels South, Belgium, facilitating the production of radioisotopes and patient doses on-site from 20251. The installation of cyclotrons from GE HealthCare and IBA (Ion Beam Applications S.A.), along with proprietary solid targets, establishes TMS Brussels South as a major nuclear medicine production facility, which will serve as the Company’s primary manufacturing site for the Europe Middle East and Africa (EMEA) region and beyond. One cyclotron will be dedicated to clinical and commercial supply, and the other to research and development (R&D), meaning TMS Brussels South will...

Q1 GAAP revenues of $568.7 million, up 4.9% from Q1 2024. Organic Q1 ASV of $2,258.8 million, up 4.5% year over year. Q1 GAAP operating margin of 33.6%, down approximately 120 bps year over year, and adjusted operating margin of 37.6%, consistent with the prior year. Q1 GAAP diluted EPS of $3.89, up 1.3% from the prior year, and adjusted diluted EPS of $4.37, up 6.1% year over year.NORWALK, Conn., Dec. 19, 2024 (GLOBE NEWSWIRE) — FactSet (“FactSet” or the “Company”) (NYSE:FDS) (NASDAQ:FDS), a global financial digital platform and enterprise solutions provider, today announced results for its first quarter fiscal 2025 ended November 30, 2024. First Quarter Fiscal 2025 HighlightsGAAP revenues increased 4.9%, or $26.5 million, to $568.7 million for the first quarter of fiscal 2025 compared with $542.2 million in the prior year...

CALGARY, Alberta, Dec. 19, 2024 (GLOBE NEWSWIRE) — The Western Investment Company of Canada Limited (TSXV: WI) (“Western” or “WICC“), today closed the over-subscribed private placement announced on August 30, 2024, and upsized on September 26, 2024, in its entirety following the receipt of $1.1 million that was outstanding. Unless otherwise indicated, financial figures are expressed in Canadian dollars. On August 30, 2024 WICC announced a private placement of units (“Units”) that was subsequently upsized on September 26, 2024 to $25 million, with an additional $5 million over-allotment at Western’s option, for aggregate gross proceeds of $30 million (the “Private Placement”). In aggregate, WICC has issued 75,000,000 Units in the Private Placement for gross proceeds of $30 million (including the 2,750,000...

~ $13 Million Convertible Debt Repayment from Available Cash ~ ~ Elimination of Approximately $1.5 Million in Annual Interest Expense and Potential Equity Overhang of Approximately 1.6 Million Shares ~ RESEARCH TRIANGLE PARK, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced the early repayment of $13 million of the Company’s approximately $32 million outstanding convertible debt facility with Petrichor Healthcare Capital Management (“Petrichor”). Pro forma for today’s announced repayment, the convertible debt facility with Petrichor will be approximately $19 million and maintain a maturity of September 2027. This early partial repayment was financed entirely with available cash. “We are pleased to announce the early partial repayment...